Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination

Cancer Gene Therapy

Volumn 17, Issue 1, 2010, Pages 11-19

  Takakura, M ^a   Nakamura, M ^a   Kyo, S ^a   Hashimoto, M ^a   Mori, N ^a   Ikoma, T ^a   Mizumoto, Y ^a   Fujiwara, T ^b   Urata, Y ^c   Inoue, M ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

Cisplatin; Oncolytic adenovirus; Ovarian cancer; Telomerase; Virotherapy

Indexed keywords

CISPLATIN; GREEN FLUORESCENT PROTEIN; OBP 301; ONCOLYTIC ADENOVIRUS; TELOMELYSIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FLUORESCENCE IMAGING; GENE EXPRESSION; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROMOTER REGION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS;

EID: 72449124142     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.44     Document Type: Article

References (34)

1. Bristow RE. Surgical standards in the management of ovarian cancer. Curr Opin Oncol 2000; 12: 474-480.
2. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10(suppl): 87-92.
3. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
4. Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002; 38: 2435-2445.
5. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000; 18: 3084-3092.
6. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
7. Barnes MN, Pustilnik TB. Current strategies in gene therapy for ovarian cancer. Curr Opin Obstet Gynecol 2001; 13: 47-51. Review.
8. Kimball KJ, Numnum TM, Rocconi RP, Alvarez RD. Gene therapy for ovarian cancer. Curr Oncol Rep 2006; 8: 441-447. Review.
9. Casado E, Nettelbeck DM, Gomez-Navarro J, Hemminki A, Gonzalez Baron M, Siegal GP et al. Transcriptional targeting for ovarian cancer gene therapy. Gynecol Oncol 2001; 82: 229-237. Review. (Pubitemid 32730596)
10. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-2563.
11. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763-771.
12. Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001; 61: 6012-6019.
13. Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G et al. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Res 2001; 61: 4405-4413.
14. Adachi Y, Reynolds PN, Yamamoto M, Wang M, Takayama K, Matsubara S et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001; 61: 7882-7888.
15. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adeno-virus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002; 62: 3438-3447.
16. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10: 285-292.
17. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998; 58: 1558-1561. (Pubitemid 28193624)
18. Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80: 60-63.
19. Kyo S, Kanaya T, Takakura M, Tanaka M, Yamashita A, Inoue H et al. Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 1999; 80: 804-809.
20. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M et al. Cloning of human telomerase reverse transcriptase gene promoter and identification of proximal core promoter essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-557.
21. Fujiwara T, Kagawa S, Kishimoto H, Endo Y, Hioki M, Ikeda Y et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 2006; 119: 432-440.
22. Hioki M, Kagawa S, Fujiwara T, Sakai R, Kojima T, Watanabe Y et al. Combination of oncolytic adenovirother-apy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. Int J Cancer 2008; 122: 2628-2633.
23. Kikuchi Y, Iwano I, Miyauchi M, Kita T, Oomori K, Kizawa I et al. The mechanism of acquired resistance to cisplatin by a human ovarian cancer cell line. Jpn J Cancer Res 1988; 79: 632-635. (Pubitemid 18152835)
24. Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004; 64: 6259-6265.
25. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006; 12: 1213-1219.
26. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 2007; 7: 191-201. Review.
27. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008; 9: 1528-1538.
28. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T et al. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999; 274: 31648-31654.
29. Fujiwara T, Tanaka N, Nemunaitis JJ, Senzer N, Tong A, Ichimaru D et al. Phase I trial of intratumorla administration of OBP-301, a novel telomerase-specific oncolytic virus in patients with advanced solid cancer: evaluation of biodistributon and immune response. J Clin Oncol 2008; 26: 171s
30. Takakura M, Kyo S, Inoue M, Wright WE, Shay JW. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 2005; 18: 8037-8043.
31. Kyo S, Takakura M, Kohama T, Inoue M. Telomerase activity in human endometrium. Cancer Res 1997; 57: 610-614.
32. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711-3715.
33. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: How can we apply them for cancer therapy? Oncogene 2002; 21: 688-697.
34. Sakurai F, Mizuguchi H, Hayakawa T. Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector. Gene Therapy 2003; 10: 1041-1048.